INTRODUCTION
Kasabach-Merritt syndrome (KMS) is the association of a hemangioma, thrombocytopenia, and hypofibrinogenemia. This phenomenon was first described in 1940 by Kasabach and Merritt, who took care of an infant with a giant capillary hemangioma and thrombocytopenic purpura.
1 KMS is a rare disorder that can affect infants from the time of birth, or may appear later in infancy as the vascular malformation grows. Diagnosis of KMS is made based on the constellation of a vascular lesion, thrombocytopenia, consumptive coagulopathy, and microangiopathic hemolytic anemia. Unlike true capillary hemangiomas that regress in childhood and are a cosmetic nuisance, the lesions in KMS are distinctive vascular tumors, that include tufted angiomas and kaposiform hemangioendotheliomas. 2 The pathophysiology is believed to be consumption of platelets and fibrinogen by intralesional thrombosis. 3 The lesions are typically superficial and solitary, but may involve internal structures such as the liver.
Cardiac failure may result from high-volume arteriovenous shunting. Shock, intracranial bleeding, or other internal hemorrhages may result in mortality rates as high as 30%. 3 Our patient had infantile KMS marked by multiple complications.
CASE REPORT
An infant was transferred to our neonatal intensive care unit in December, 2002 with the diagnosis of a giant capillary hemangioma and suspected KMS. The infant was a 2 week old, full-term, 3352-g male, born at another facility. After birth he was noted to have a large (5 cm Â 8 cm) hemangioma on his left upper extremity ( Figure 1 ). During his first 2 weeks of life, the arm with the hemangioma was wrapped with a compression bandage and he received transfusions of fresh frozen plasma and packed red blood cells. He did not require a platelet transfusion, as his platelet count ranged from 79,000 to 132,000. On the day of transfer, he was noted to have hematuria and a platelet count of 59,000. Upon admission to our facility, this progressed to gross hematuria with large clots. Initial labs showed a platelet count of <10,000 (nl. 150 to 400,000), hematocrit of 29% (nl. 42 to 50), fibrinogen of 91 mg/dl (nl. 170 to 300), D-dimer of >0.50 mcg/ml (nl <0.26), and a normal PT/PTT and renal function. Renal ultrasound demonstrated the presence of a right renal parenchymal hematoma with moderate, right-sided hydronephrosis ( Figure 2a ). The collecting system contained echogenic material consistent with blood. The bladder contained swirling debris and a 2 to 3 cm echogenic clot obstructing the bladder outlet (Figure 2b) . A catheter was inserted into the bladder under ultrasound guidance. A measure of 164 cm 3 of bloody urine was obtained within the first 3 hours.
After consultation with hematology, methylprednisolone (2 mg/kg/day) was begun and the patient was transfused platelets, cryoprecipitate, and packed red blood cells. By the second day, the hematuria had decreased, the coagulopathies had stabilized, and he required no further transfusions. At discharge, a renal ultrasound showed improvement in the renal parenchymal hematoma and resolution of the clot within the bladder. The patient was discharged from hospital on day 7 with instructions to continue the methylprednisolone. At follow-up, the lesion had grown slightly in size, but the patient's hematologic parameters remained stable. A methylprednisolone taper was begun.
This infant returned to our hospital emergency room at 2 months of age with a 2-day history of emesis that had become bilious. An abdominal ultrasound was performed that showed an intussusception with a lead point. A pneumatic enema was performed that showed that the lead point was in the proximal jejunum. Because small bowel intussusceptions are not reducible by enema, the patient was taken to the operating room where a mass was found arising from the mucosal surface of the jejunum. Several smaller lesions were found in the vicinity of the lead point. These areas were resected and were sent to pathology where they were found to contain multiple Kaposi-like infantile hemangioendotheliomas, lesions associated with Kasabach-Merritt syndrome.
The infant recovered well from surgery, but had continued growth of the lesion on his arm. He became coagulopathic and required platelet, cryoprecipitate, and red blood cell transfusions. Before placement of a port-a-cath in his left upper chest, he was transfused platelets and cryoprecipitate. Vincristine (0.025 mg/kg/ dose) was then initiated on a weekly basis. After 6 weeks of vincristine treatment, there was no change in the lesion or in the infant's hematologic parameters. He was hospitalized once for ileus, thought to be secondary to vincristine. Due to this infant's life-threatening complications, pediatric surgery was consulted. A CT angiogram showed the lesion to be primarily supplied by a branch of the ulnar artery, without involvement of major vessels or nerves of the arm. Excision was recommended. The infant was transfused with cryoprecipitate, and a successful operation was performed to remove the hemangioma from the arm. No skin grafts were required and the child has full use of his arm. The infant has had no bleeding abnormalities since this surgery and no further hematuria.
DISCUSSION
Renal hematomas presenting in the neonate are extremely rare; our search found only one other reported case. 4 Similarly, gastrointestinal hemangiomas are also rare and make up 0.05% of all intestinal neoplasms. 5 Our patient, who had a giant capillary hemangioma on his forearm and KMS, unfortunately encountered both in his short life. Medical attempts with high-dose steroids and vincristine failed to treat our patient's hemangiomas. Surgical resection of his vascular tumor was curative, but it should be noted that surgery carries a high intraoperative mortality rate. For many, resection is often impossible or disfiguring due to the location of the lesion.
Treatment options for KMS include radiation therapy, interferon alpha, Amicar, embolization, corticosteroids, ticlopidine and aspirin, and vincristine. 6, 7 Corticosteroids are the usual first-line treatment as they carry a lower risk and have fewer side effects than other treatment modalities. The dose is tapered to the lowest dose that sustains a normal platelet count and normal fibrinogen level; steroids are often required for several months. Other treatments are added if the consumptive coagulopathy and thrombocytopenia continue despite steroids. Supportive care includes transfusion of platelets and cryoprecipitate to replace fibrinogen and correct the coagulopathy. The natural course of the syndrome is resolution in childhood, as the vascular lesions usually resolve by school age.
This case should serve to remind clinicians of the possible complications that may be encountered with KMS and serve as a report of one infant's unusual presentation.
